Analysts Set Coherus Oncology, Inc. (NASDAQ:CHRS) Price Target at $4.51

Shares of Coherus Oncology, Inc. (NASDAQ:CHRS) have received an average rating of “Hold” from the five ratings firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $4.5125.

Several equities research analysts have recently weighed in on CHRS shares. Maxim Group raised shares of Coherus Oncology from a “hold” rating to a “buy” rating and set a $4.00 price target for the company in a research report on Thursday, September 4th. Weiss Ratings reissued a “sell (d)” rating on shares of Coherus Oncology in a research report on Wednesday, October 8th.

Institutional Investors Weigh In On Coherus Oncology

A number of hedge funds and other institutional investors have recently bought and sold shares of CHRS. Voya Investment Management LLC purchased a new stake in Coherus Oncology during the third quarter valued at approximately $28,000. International Assets Investment Management LLC purchased a new stake in Coherus Oncology during the second quarter valued at approximately $33,000. CWM LLC lifted its position in Coherus Oncology by 96.6% during the first quarter. CWM LLC now owns 49,793 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 24,468 shares during the last quarter. Corient Private Wealth LLC lifted its position in Coherus Oncology by 20.0% during the second quarter. Corient Private Wealth LLC now owns 60,000 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 10,000 shares during the last quarter. Finally, Cerity Partners LLC increased its stake in Coherus Oncology by 84.0% during the 1st quarter. Cerity Partners LLC now owns 54,676 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 24,953 shares in the last quarter. Hedge funds and other institutional investors own 72.82% of the company’s stock.

Coherus Oncology Price Performance

Shares of CHRS opened at $1.60 on Tuesday. The company has a 50 day moving average price of $1.53 and a 200-day moving average price of $1.12. Coherus Oncology has a fifty-two week low of $0.66 and a fifty-two week high of $2.43. The stock has a market capitalization of $185.97 million, a PE ratio of 1.03 and a beta of 0.96. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.43 and a current ratio of 1.44.

About Coherus Oncology

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.